U.S. FDA panel backs Aerie’s glaucoma drug Rhopressa

(Reuters) – Aerie Pharmaceuticals Inc's experimental glaucoma treatment should be approved, an advisory committee to the U.S. Food and Drug Administration said on Friday, after it found the benefits outweigh the risks.
Original Article

more recommended stories